Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(10 sites) United States
Yale University, New Haven, Connecticut Mayo Clinic Florida, Jacksonville, Florida Northwestern Memorial Hospital, Chicago, Illinois The University of Chicago Medical Center, Chicago, Illinois University of Kansas Medical Center, Kansas City, Kansas University of Michigan, Ann Arbor, Michigan Mayo Clinic Rochester, Rochester, Minnesota Columbia University Irving Medical Center, New York, New York University of Rochester, Rochester, New York Duke University, Durham, North Carolina